Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present TapImmune, Inc. (OTC: TPIV).

Full DD Report for TPIV

You must become a subscriber to view this report.


Recent News from (OTC: TPIV)

Today's Research Reports on Stocks to Watch: Innovate Biopharmaceuticals and TapImmune
NEW YORK, NY / ACCESSWIRE / September 4, 2018 / Both Innovate Biopharmaceuticals and TapImmune sprang to life on Friday seeing big gains after the companies announced plans to present at conferences this month. RDI Initiates Coverage on: Innovate Biopharmaceuticals, Inc. https://rdi...
Source: ACCESSWIRE IA
Date: September, 04 2018 08:00
3 Cancer Treatment Stocks that Moved Higher in August
CORAL GABLES, FL / ACCESSWIRE / August 31, 2018 / August was a busy month for regulatory moves in terms of Novel Drug approvals. We also saw the ongoing efforts to restrict opioid abuse, and new initiatives to bolster new advances in the rapidly evolving field of gene therapy. Eight Novel D...
Source: ACCESSWIRE IA
Date: August, 31 2018 12:45
Midday Gainers / Losers (08/31/2018)
Gainers:  AOBC +37% . PDEX +23% . TLYS +19% . INNT +19% . GGAL +19% . BMA +19% . TPIV +18% . SUPV +17% . EDN +16% . LULU +16% . More news on: American Outdoor Brands Corporation, Pro-Dex, Inc., Tilly's, Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: August, 31 2018 12:42
TapImmune to Participate at Two Upcoming Industry Conferences
JACKSONVILLE, Fla. , Aug. 29, 2018 /PRNewswire/ -- TapImmune Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company, today announced that its President and CEO, Peter L. Hoang , will participate at two upcoming industry conferences.  Mr. Hoang will present and participate in...
Source: PR Newswire
Date: August, 29 2018 06:30
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Tapimmune, Inc. - TPIV
NEW YORK , Aug. 3, 2018 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City , is investigating Tapimmune, Inc. ("Tapimmune" or the "Company") (NasdaqCM...
Source: PR Newswire
Date: August, 03 2018 10:00
Complimentary Technical Snapshots on Viking Therapeutics and Three More Biotech Stocks
Stock Research Monitor: TPIV, VCEL, and VRTX LONDON, UK / ACCESSWIRE / July 25, 2018 / If you want a free Stock Review on VKTX sign up now at www.wallstequities.com/registration . On Tuesday, July 24, 2018, US markets sawsevenout of nine sectors finishing the day ingreen and two in red...
Source: ACCESSWIRE IA
Date: July, 25 2018 07:45
Galectin Therapeutics IPF Patent Solidifies Platform Technology Status
Galectin Therapeutics (NASDAQ: GALT ) announced on June 27th its patent for the method and treatment of Idiopathic Pulmonary Fibrosis (IPF). The significance of this patent was initially received as extremely positive by the market, but recent structural pressures like the option exercise ...
Source: SeekingAlpha
Date: July, 05 2018 14:46
A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals
Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. Biotech holds a special place in my heart, both for the way it captures the imagination and for...
Source: SeekingAlpha
Date: June, 16 2018 09:00
Midday Gainers / Losers (06/15/2018)
Gainers:  CLPS +34% . GOOS +27% . NDRA +24% . BAK +19% . TPIV +19% . VSTM +16% . CFRX +15% . NETE +14% . TCI +14% . NEWA +13% . More news on: CLPS, Inc, Canada Goose Holdings, Endra Life Sciences Inc, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: June, 15 2018 12:36
Your Daily Pharma Scoop: Secondaries Review June 4-11
A discussion of secondary offerings provides interesting analysis of a company. There are two kinds of secondary offerings; one, the non-dilutive kind, where no new shares are issued, but a large institutional shareholder simply releases a large block of previously issued shares. Two, a diluti...
Source: SeekingAlpha
Date: June, 12 2018 10:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-10-178.268.348.408.01100,553
2018-10-167.828.298.4157.6761201,686
2018-10-157.507.747.90257.35204,154
2018-10-128.017.438.20997.3035217,524
2018-10-118.627.888.847.64304,973

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2016-11-076,99423,25130.0804Cover
2016-11-045,85720,53228.5262Cover
2016-11-032,6769,26128.8954Cover
2016-11-021802,1118.5268Cover
2016-11-013,3457,22846.2784Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on TPIV.


About TapImmune, Inc. (OTC: TPIV)

Logo for TapImmune, Inc. (OTC: TPIV)

Cancer and viral disease immunotherapy products R amp D company

 

 

 

Current Management

  • Glynn Wilson / CEO
  • John Bonfiglio / President, COO
    • Dr. Bonfiglio has broad experience in corporate strategy and financing, market interactions and business development. He was most recently President and CEO of Oragenics where he refocused the company and raised over million dollars in the public markets while positioning the company for a successful relisting on the NYSE: MKT stock exchange. He was formerly President and CEO of Argos Therapeutics where he raised over million dollars for the Company and led the company in a successful Phase study in renal cell carcinoma. As President and CEO of the Immune Response Corporation he was responsible for turning the Company around through improved therapeutic focus, capital raising over million and improved investor relations resulting in a significant increase in stock price and shareholder value. John was also President and CEO of Peregrine Pharmaceuticals and Director of Business Development at Baxter Healthcare Corporation s Immunotherapy Division. John has a Ph.D from the University of California, San Diego, and an MBA from Pepperdine University. As a result of his appointment, the number of our board directors has increased from four to five.
  • Michael Joseph Loiacono / CFO, Chief Accounting Officer, Secretary, Treasurer
  • Glynn Wilson / Chairman
  • John Bonfiglio / Dr. Bonfiglio has broad experience in corporate strategy and financing, market interactions and business development. He was most recently President and CEO of Oragenics where he refocused the company and raised over million dollars in the public markets while positioning the company for a successful relisting on the NYSE: MKT stock exchange. He was formerly President and CEO of Argos Therapeutics where he raised over million dollars for the Company and led the company in a successful Phase study in renal cell carcinoma. As President and CEO of the Immune Response Corporation he was responsible for turning the Company around through improved therapeutic focus, capital raising over million and improved investor relations resulting in a significant increase in stock price and shareholder value. John was also President and CEO of Peregrine Pharmaceuticals and Director of Business Development at Baxter Healthcare Corporation s Immunotherapy Division. John has a Ph.D from the University of California, San Diego, and an MBA from Pepperdine University. As a result of his appointment, the number of our board directors has increased from four to five.
  • Sherry Grisewood /
  • David LaskowPooley /
  • Mark Reddish /
  • Frederick G. Wasserman / Mr. Wasserman is a business executive with over years of business experience, having served at various companies in roles including Chief Executive Officer, President, Chief Operating Officer and Chief Financial Officer. He is currently the President of FGW Partners LLC, Pennington, NJ, where he has been employed since . He currently serves on the boards of directors of several public companies. Mr. Wasserman was employed as a certified public accountant from to . He earned a Bachelor of Science degree from The Wharton School at The University of Pennsylvania in .

Current Share Structure

  • Market Cap: $37,308,262 - 03/09/2018
  • Authorized: 41,666,667 - 09/16/2016
  • Issue and Outstanding: 10,539,057 - 11/01/2017
  • Float: 6,759,749 - 09/16/2016

 


Recent Filings from (OTC: TPIV)

Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: May, 16 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 15 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: May, 15 2018
Filing by person(s) reporting owned shares of common stock in a public company >5%
Filing Type: SC 13DFiling Source: edgar
Filing Date: April, 04 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 23 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: March, 23 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: January, 26 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: December, 29 2017

 

 


Daily Technical Chart for (OTC: TPIV)

Daily Technical Chart for (OTC: TPIV)


Stay tuned for daily updates and more on (OTC: TPIV)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: TPIV)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in TPIV is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of TPIV and does not buy, sell, or trade any shares of TPIV. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/